Teva Pharmaceutical Industries Ltd. is advancing TEV-’408, an investigational anti-interleukin (IL)-15 monoclonal antibody, into Phase 2b development in vitiligo in the fourth quarter of 2026.
TEV-’408 is designed for quarterly dosing.
The decision to advance development follows encouraging results from an ongoing Phase 1b, open-label study in adults with active or stable non-segmental vitiligo (NSV). The study showed improvements in skin pigmentation in patients with active or stable NSV.
In addition, TEV-’408 was well-tolerated with no safety signals observed to date.
At baseline, 66% of enrolled participants had vitiligo affecting more than 10% of body surface area, representing a population with limited treatment options.
At Week 24, in evaluable participants:
Nearly 75% of patients reported improvement in facial vitiligo, with half reporting “much” or “very much” improved
Fully 42% achieved Facial Vitiligo Area Scoring Index(F-VASI) 50 and 21% achieved F-VASI75
Fifty-five percent of patients reported improvement in total body vitiligo
Seven percent achieved Total Vitiligo Area Scoring Index (T-VASI) 50
